The Role of Stress Neuromodulators in Decision Making Under Risk and Selective Attention to Threat
NCT04359147 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 167
Last updated 2022-03-15
Summary
Incidental affective states, i.e., affective states can influence decision making and selective attention to threatening information. Acute stress is such an affective state and is a powerful contextual modulator of decision-making processes and selective attention to threat. In terms of physiological and neurohormonal changes, the stress response has been well characterized: Exposure to stress elicits an array of autonomic, endocrine, and behavioral responses. The physiological stress response is mediated by the hypothalamic-pituitary-adrenal (HPA) axis and the locus coeruleus noradrenergic (LC-NA) system with cortisol and norepinephrine (NE) as their end products. There is compelling evidence that the stress hormones cortisol and NE influence cognitive processes. However, only very few studies so far used pharmacological approaches to specify the role of stress neuromodulators on decision making and selective attention to threat and these studies are hardly comparable due to differences in the experimental design, e.g., the decision making task used. Furthermore, the neural underpinnings of stress effects on decision making and selective attention to threat are uninvestigated so far. The aim of the proposed project is to clarify the role of the major stress neuromodulators, NE and cortisol, in their contribution to different processes related to decision making under risk and selective attention to threat. To this end, combined precise pharmacological stimulation, behavioral modeling, and fMRI methods will be applied to systematically disentangle the effects of stress hormones on risk attitudes and loss aversion as well as their relation to neural correlates of processing subjective value and risk. Using pharmacological manipulation, the influence of noradrenergic and glucocorticoid activity on decision making under risk at the behavioral, computational, and neural level will be investigated. In addition, the influence of noradrenergic and glucocorticoid activity on selective attention to threat at the behavioural and neural level using a dot-probe paradigm with fearful and neutral faces will be examined. Participants are randomly assigned to one of four groups: (A) yohimbine, (B) hydrocortisone, (C) yohimbine and hydrocortisone, or (D) placebo.
Conditions
- Yohimbine
- Hydrocortisone
- Yohimbine + Hydrocortisone
- Placebo
Interventions
- DRUG
-
"Yohimbine"
Effects on neural correlates of decision-making under risk and selective attention to threat
- DRUG
-
"Hydrocortisone"
Effects on neural correlates of decision-making under risk and selective attention to threat
- DRUG
-
"Yohimbine + Hydrocortisone"
Effects on neural correlates of decision-making under risk and selective attention to threat
- DRUG
-
"Placebo"
Effects on neural correlates of decision-making under risk and selective attention to threat
Sponsors & Collaborators
-
Charite University, Berlin, Germany
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 35 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-11-01
- Primary Completion
- 2021-12-22
- Completion
- 2021-12-22
Countries
- Germany
Study Locations
More Related Trials
-
Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress
NCT02904109 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study
NCT04080427 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects
NCT04173962 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Huperzine A in Treatment of Moderate to Severe TBI
NCT01676311 ·Status: TERMINATED ·Phase: PHASE2
-
Characterization of the Prosocial and Prosexual Effects of GHB
NCT02342366 ·Status: COMPLETED ·Phase: NA
-
The Effect of Dronabinol on the Acquisition and Consolidation of Trauma-Associated Memories
NCT04871269 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder
NCT04231708 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol
NCT04448808 ·Status: COMPLETED ·Phase: PHASE2
-
A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
NCT00457366 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction
NCT03527316 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Inhibitory Control: Effects of Modulation
NCT04247334 ·Status: RECRUITING ·Phase: NA
-
The Human Stress Response in a Simulated ED Setting
NCT04317482 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The Effect of D-cycloserine on Emotional Processing
NCT03961464 ·Status: COMPLETED ·Phase: NA
-
Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study
NCT03008005 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury
NCT02321761 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluation of MDMA on Startle Response
NCT03181763 ·Status: COMPLETED ·Phase: PHASE1
-
MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer
NCT00252174 ·Status: TERMINATED ·Phase: PHASE2
-
Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task
NCT04778644 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Effects of THC and CBD on Human Episodic Memory Function
NCT02291562 ·Status: COMPLETED ·Phase: NA
-
Cannabinoids, Neural Synchrony, and Information Processing
NCT00708994 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)
NCT00970944 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder
NCT00353938 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.
NCT03752918 ·Status: WITHDRAWN ·Phase: PHASE1
-
Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder
NCT02069366 ·Status: COMPLETED ·Phase: NA
-
Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study
NCT01951508 ·Status: COMPLETED ·Phase: EARLY_PHASE1